If you are an R&D “lifer” as I am, particularly one who spent 30 years with Pfizer PFE -0.13%, you have to be a bit worried about the Pfizer-Allergan deal. The worry stems not from all the talk about inversions and tax avoidance, but rather about Brent Saunders, current Allergan AGN +2.80% CEO and the future president and COO of the newly combined company. After all, this is the person who told Forbes last January that “the idea that to play in the big leagues you have to do drug discovery is a fallacy.”
